|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SELENOH |
Gene summary for SELENOH |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SELENOH | Gene ID | 280636 |
| Gene name | selenoprotein H | |
| Gene Alias | C11orf31 | |
| Cytomap | 11q12.1 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q8IZQ5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 280636 | SELENOH | Pat07-B | Human | Stomach | GC | 4.10e-26 | 8.54e-01 | 0.0935 |
| 280636 | SELENOH | Pat08-B | Human | Stomach | GC | 1.03e-27 | 8.80e-01 | 0.0182 |
| 280636 | SELENOH | Pat09-B | Human | Stomach | GC | 9.46e-27 | 5.78e-01 | -0.0359 |
| 280636 | SELENOH | Pat10-B | Human | Stomach | GC | 1.34e-21 | 7.55e-01 | 0.084 |
| 280636 | SELENOH | Pat11-B | Human | Stomach | GC | 7.66e-42 | 8.96e-01 | -0.182 |
| 280636 | SELENOH | Pat12-B | Human | Stomach | GC | 2.15e-62 | 9.44e-01 | 0.0325 |
| 280636 | SELENOH | Pat13-B | Human | Stomach | GC | 5.96e-32 | 7.49e-01 | 0.0555 |
| 280636 | SELENOH | Pat15-B | Human | Stomach | GC | 8.98e-37 | 6.93e-01 | -0.0778 |
| 280636 | SELENOH | Pat16-B | Human | Stomach | GC | 2.62e-51 | 8.79e-01 | 0.1918 |
| 280636 | SELENOH | Pat17-B | Human | Stomach | GC | 4.07e-37 | 7.70e-01 | 0.3109 |
| 280636 | SELENOH | Pat18-B | Human | Stomach | GC | 6.67e-42 | 6.96e-01 | -0.0432 |
| 280636 | SELENOH | Pat19-B | Human | Stomach | GC | 4.86e-36 | 7.12e-01 | 0.0826 |
| 280636 | SELENOH | Pat22-B | Human | Stomach | GC | 1.38e-45 | 6.82e-01 | -0.1042 |
| 280636 | SELENOH | Pat24-B | Human | Stomach | GC | 7.65e-44 | 9.39e-01 | -0.1184 |
| 280636 | SELENOH | Pat25-A | Human | Stomach | CAG with IM | 1.63e-73 | 9.39e-01 | -0.1648 |
| 280636 | SELENOH | Pat26-A | Human | Stomach | CSG | 8.60e-87 | 1.06e+00 | -0.2402 |
| 280636 | SELENOH | Pat28-A | Human | Stomach | CSG | 1.41e-53 | 9.68e-01 | -0.2594 |
| 280636 | SELENOH | Pat29-A | Human | Stomach | CAG with IM | 3.26e-41 | 1.07e+00 | -0.2769 |
| 280636 | SELENOH | male-WTA | Human | Thyroid | PTC | 2.61e-10 | 1.53e-01 | 0.1037 |
| 280636 | SELENOH | PTC01 | Human | Thyroid | PTC | 5.36e-55 | 1.18e+00 | 0.1899 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SELENOH | SNV | Missense_Mutation | c.85G>C | p.Glu29Gln | p.E29Q | Q8IZQ5 | protein_coding | tolerated(0.28) | benign(0) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| SELENOH | SNV | Missense_Mutation | c.334G>C | p.Glu112Gln | p.E112Q | Q8IZQ5 | protein_coding | tolerated(0.36) | benign(0.001) | TCGA-G4-6627-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| SELENOH | SNV | Missense_Mutation | novel | c.34N>A | p.Ala12Thr | p.A12T | Q8IZQ5 | protein_coding | deleterious(0.05) | benign(0.326) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| SELENOH | SNV | Missense_Mutation | novel | c.287N>T | p.Gly96Val | p.G96V | Q8IZQ5 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
| SELENOH | SNV | Missense_Mutation | novel | c.121N>C | p.Cys41Arg | p.C41R | Q8IZQ5 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| SELENOH | SNV | Missense_Mutation | novel | c.351N>T | p.Leu117Phe | p.L117F | Q8IZQ5 | protein_coding | deleterious(0.04) | probably_damaging(0.999) | TCGA-EO-A22X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | Complete Response |
| SELENOH | SNV | Missense_Mutation | novel | c.224G>A | p.Arg75Gln | p.R75Q | Q8IZQ5 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-21-1081-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |